# Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

> **NCT03013933** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 29 (actual)

## Conditions studied

- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Cyclosporine
- **OTHER:** Pharmacokinetic Study
- **DRUG:** Verapamil
- **DRUG:** Verapamil Hydrochloride

## Key facts

- **NCT ID:** NCT03013933
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-03
- **Primary completion:** 2022-05-24
- **Final completion:** 2022-05-24
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-02-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03013933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03013933, "Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03013933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*